Flow Cytometry Shared Resource

流式细胞术共享资源

基本信息

项目摘要

The Flow Cytometry Shared Resource (FCSR) provides state-of-the-art analytical and sorting instrumentation as well as cutting-edge expertise, at an affordable cost, to UCLA investigators needing flow cytometry to pursue their research. The Jonsson Comprehensive Cancer Center (JCCC) established this campus-wide shared resource in 1988. Dr. Jamieson (Tl), an accomplished cellular immunologist, has been the Director of the FCSR since 2000. Ms. Schmid, the manager of the FCSR since 1988, is responsible for the daily operation of the FCSR and assists Dr. Jamieson (Tl) with long-term planning. Both Dr. Jamieson (Tl) and Ms. Schmid are available to users for consultation. To achieve its goals, the FCSR provides five analytic flow cytometers, three high-speed digital cell sorters, an AutoMACS cell separator and a free-standing analysis station. The FCSR is easily accessible and is responsible for procurement, daily calibration, maintenance and repair of all instrumentation. FCSR personnel have a combined 82 years of experience in flow cytometry; their expertise is available to investigators through one-on-one consultation, classes, a website, poster presentations and open houses. Ms. Schmid and Dr. Jamieson (Tl) also work with researchers to adapt, or develop, assays to enable investigators to pursue research questions in novel ways. FCSR services help researchers with a wide range of experience in flow cytometry to perform high quality assays, with minimal time expenditure. Workshops, seminars and utilization of new assays ensure that researchers remain on the cutting-edge of flow cytometry without the necessity of investing their own funds or staff time to keep current in the latest advances. Cytometric instrumentation is expensive and beyond the budget of most individual researchers; therefore, the FCSR provides instrumentation, as well as additional cost savings to researchers, by obtaining grant and institutional support to help offset the cost of purchasing, maintaining and operating those instruments. The cost savings are passed on to the researcher. During the last funding period, a total of 254 investigators used the FCSR. Between July 1, 2006, through June 30, 2007 (the reporting period for the CCSG competing renewal), JCCC members were responsible for 76% of the usage. These data objectively demonstrate the role of the FCSR in enhancing cancer research at UCLA and its contribution to JCCC's effort to improving diagnosis, therapy and cure of cancer patients. (Please also see Section 6.2.3 on Shared Resources in the History, Description, Essential Characteristics). 86 Cancer Center members representing 11 Cancer Center Program Areas utilized the services of the Flow Cytometry Shared Resource during the reporting period. This is a continuing shared resource.
流式细胞术共享资源(FCSR)提供最先进的分析和分选 仪器以及尖端的专业知识,以负担得起的成本,加州大学洛杉矶分校的调查人员需要流动 cytometry细胞计数to pursue追求their其research研究.琼森综合癌症中心(JCCC)建立了这一 1988年的校园共享资源。Jamieson博士(TI)是一位有成就的细胞免疫学家, 自2000年起担任社会研究基金会主任。Schmid女士自1988年以来一直担任FCSR的经理, 负责FCSR的日常运作,并协助Jamieson博士(TL)进行长期规划。两 博士Jamieson(Tl)和Schmid女士可供用户咨询。为了实现其目标, 提供五台流式细胞仪、三台高速数字细胞分选仪、一台AutoMACS细胞分离器, 独立的分析站财务、社会和资源中心很容易联系,负责日常采购工作。 所有仪表的校准、维护和修理。FCSR员工共有82年的工作经验, 在流式细胞术方面的经验;他们的专业知识可通过一对一的咨询提供给研究者, 课程,网站,海报展示和开放日。Schmid女士和Jamieson博士(TL)也在 与研究人员适应,或开发,测定,使研究人员能够追求新的研究问题, 的方式FCSR服务帮助在流式细胞术方面拥有广泛经验的研究人员进行高水平的 高质量的分析,以最少的时间消耗。讲习班、研讨会和新检测方法的使用确保 研究人员保持在流式细胞术的前沿,而无需投资自己的 资金或工作人员的时间,以保持目前的最新进展。细胞计数仪器昂贵, 超出了大多数研究人员的预算;因此,FCSR提供仪器,以及 通过获得赠款和机构支持,帮助抵消 购买、维护和操作这些仪器。节省的成本转嫁到 研究员在上一个资助期内,共有254名研究者使用了FCSR。7月1日, 2006年至2007年6月30日(CCSG竞争性更新的报告期),JCCC成员 占使用量的76%。这些数据客观地证明了《家庭社会责任报告》在加强 加州大学洛杉矶分校的癌症研究及其对JCCC改善癌症诊断、治疗和治愈的贡献 癌症患者。(另请参见第6.2.3节关于共享资源的历史,描述,基本 特征)。 代表11个癌症中心项目区的86名癌症中心成员利用了 报告期间的流式细胞术共享资源。这是一个持续的共享资源。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Beth Deirdre Jamieson-Karavodin其他文献

Beth Deirdre Jamieson-Karavodin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Beth Deirdre Jamieson-Karavodin', 18)}}的其他基金

Durability of immune responses to SARS-CoV-2 infection in the context of HIV-infection, aging and cross-reactive immune responses.
HIV 感染、衰老和交叉反应免疫反应背景下对 SARS-CoV-2 感染的免疫反应的持久性。
  • 批准号:
    10188882
  • 财政年份:
    2016
  • 资助金额:
    $ 33.26万
  • 项目类别:
Characterizing the Epigenetic relationship between aging, HIV-infection, ART and biological outcomes
表征衰老、HIV 感染、ART 和生物学结果之间的表观遗传关系
  • 批准号:
    9753079
  • 财政年份:
    2016
  • 资助金额:
    $ 33.26万
  • 项目类别:
Characterizing the Epigenetic relationship between aging, HIV-infection, ART and biological outcomes
表征衰老、HIV 感染、ART 和生物学结果之间的表观遗传关系
  • 批准号:
    9065269
  • 财政年份:
    2016
  • 资助金额:
    $ 33.26万
  • 项目类别:
Cytometry Core
细胞计数核心
  • 批准号:
    8377981
  • 财政年份:
    2012
  • 资助金额:
    $ 33.26万
  • 项目类别:
Cytometry Core
细胞计数核心
  • 批准号:
    8230853
  • 财政年份:
    2011
  • 资助金额:
    $ 33.26万
  • 项目类别:
SORP BD FACSAria II
SORP BD FACSAria II
  • 批准号:
    7595159
  • 财政年份:
    2009
  • 资助金额:
    $ 33.26万
  • 项目类别:
Protective roles of CTL responses to HIV-1 associated self epitope
CTL 对 HIV-1 相关自身表位反应的保护作用
  • 批准号:
    7790553
  • 财政年份:
    2009
  • 资助金额:
    $ 33.26万
  • 项目类别:
Synergistic effects of HIV and age on naive CD4+ T-cell senescence
HIV 和年龄对幼稚 CD4 T 细胞衰老的协同作用
  • 批准号:
    8310978
  • 财政年份:
    2008
  • 资助金额:
    $ 33.26万
  • 项目类别:
Synergistic effects of HIV and age on naive CD4+ T-cell senescence
HIV 和年龄对幼稚 CD4 T 细胞衰老的协同作用
  • 批准号:
    7679053
  • 财政年份:
    2008
  • 资助金额:
    $ 33.26万
  • 项目类别:
Cytometry Core
细胞计数核心
  • 批准号:
    7480730
  • 财政年份:
    2008
  • 资助金额:
    $ 33.26万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 33.26万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 33.26万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 33.26万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.26万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 33.26万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 33.26万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 33.26万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 33.26万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 33.26万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 33.26万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了